Amgen (AMGN) stock jumped 4% Tuesday after its dazodalibep Phase 3 Sjögren's trial met its primary endpoint with no approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results